News
Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback